Mar 11, 2026 at 3:50 AM#6
Those metabolic outcomes are excellent and track closely with published trial data. The 17-18% body weight reduction over 10 months at 10-15mg tirz dosing is right in the expected range (SURMOUNT-1 showed 20.9% at 15mg over 72 weeks).
The lipid improvements are particularly noteworthy — LDL down 27%, triglycerides down 43%. Those are statin-like improvements from a GLP-1/GIP agonist. Your cardiovascular risk profile has meaningfully improved.
One suggestion: add liver enzymes (ALT, AST) to your monitoring panel if you're not already. There have been rare reports of transaminase elevations with GLP-1RAs, particularly in the context of rapid weight loss and fatty liver disease resolution. Not a concern per se, but worth tracking.
15 1mike_mealprep, NicoleRaleigh, james_edin and 12 others
Reply Quote Save Share Report